Myocardial Ischemia - Pipeline Review, H2 2016

Date: August 31, 2016
Pages: 84
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M3A31D1D185EN
Leaflet:

Download PDF Leaflet

Myocardial Ischemia - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Myocardial Ischemia - Pipeline Review, H2 2016’, provides an overview of the Myocardial Ischemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Myocardial Ischemia
  • The report reviews pipeline therapeutics for Myocardial Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Myocardial Ischemia therapeutics and enlists all their major and minor projects
  • The report assesses Myocardial Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Myocardial Ischemia
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Myocardial Ischemia Overview
Therapeutics Development
Pipeline Products for Myocardial Ischemia - Overview
Pipeline Products for Myocardial Ischemia - Comparative Analysis
Myocardial Ischemia - Therapeutics under Development by Companies
Myocardial Ischemia - Therapeutics under Investigation by Universities/Institutes
Myocardial Ischemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Myocardial Ischemia - Products under Development by Companies
Myocardial Ischemia - Products under Investigation by Universities/Institutes
Myocardial Ischemia - Companies Involved in Therapeutics Development
Bayer AG
Cellmid Limited
CohBar, Inc.
Lixte Biotechnology Holdings, Inc.
Miltenyi Biotec GmbH
NoNO, Inc.
Shire Plc
Symic Biomedical, Inc.
Taxus Cardium Pharmaceuticals Group Inc.
ViroMed Co., Ltd.
Myocardial Ischemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AB-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alda-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alferminogene tadenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AntimiR-199a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-606583 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMK-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-80317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Humanin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMC-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-030 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Cardiovascular Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VM-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myocardial Ischemia - Dormant Projects
Myocardial Ischemia - Discontinued Products
Myocardial Ischemia - Product Development Milestones
Featured News & Press Releases
May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities
Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City
Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology
Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention
Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings
May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy
Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease
Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy
Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study
Feb 28, 2012: Baxter Initiates Phase III Adult Stem Cell Clinical Trial For Chronic Cardiac Condition
Jun 15, 2011: Cardium Therapeutics's Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Coronary Artery Disease
Nov 03, 2010: Cardium Awarded Grant Under QTDP Program
Dec 08, 2006: Cardium's Generx Advances To Phase III Following Meeting With FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Myocardial Ischemia, H2 2016
Number of Products under Development for Myocardial Ischemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Myocardial Ischemia - Pipeline by Bayer AG, H2 2016
Myocardial Ischemia - Pipeline by Cellmid Limited, H2 2016
Myocardial Ischemia - Pipeline by CohBar, Inc., H2 2016
Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016
Myocardial Ischemia - Pipeline by Miltenyi Biotec GmbH, H2 2016
Myocardial Ischemia - Pipeline by NoNO, Inc., H2 2016
Myocardial Ischemia - Pipeline by Shire Plc, H2 2016
Myocardial Ischemia - Pipeline by Symic Biomedical, Inc., H2 2016
Myocardial Ischemia - Pipeline by Taxus Cardium Pharmaceuticals Group Inc., H2 2016
Myocardial Ischemia - Pipeline by ViroMed Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Myocardial Ischemia - Dormant Projects, H2 2016
Myocardial Ischemia - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Myocardial Ischemia, H2 2016
Number of Products under Development for Myocardial Ischemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Bayer AG
Cellmid Limited
CohBar, Inc.
Lixte Biotechnology Holdings, Inc.
Miltenyi Biotec GmbH
NoNO, Inc.
Shire Plc
Symic Biomedical, Inc.
Taxus Cardium Pharmaceuticals Group Inc.
ViroMed Co., Ltd.
Skip to top


Ischemia - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 223 pages

Ask Your Question

Myocardial Ischemia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: